Form 4: Acrivon Therapeutics Director Michael Tomsicek Acquires Stock Options

Director Michael Tomsicek acquired 20,275 stock options in Acrivon Therapeutics on June 20, 2024.

Summary

• Michael Tomsicek, a director of Acrivon Therapeutics, Inc., acquired 20,275 stock options on June 20, 2024.
• The exercise price of these options is $6.52.
• The options vest on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent upon continuous service.
• Tomsicek also granted a Power of Attorney to Peter Blume-Jensen, Rasmus Holm-Jorgensen, Eric Devroe, Katharine Peterson and Mary-Alice Miller to handle SEC filings.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of options by a director could be interpreted as a mildly positive signal, reflecting confidence in the company, but it's not a strong indicator.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to the director's continuous service and the company's annual meeting.

Industry Context

This is a standard SEC filing related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are a standard requirement for company insiders in the US, ensuring transparency in their trading activities.
• The vesting schedule of the options is typical, often tied to continued employment or service.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates